Trump begins EU trade discussions at golf resort meeting in Scotland
Make-or-break talks could head off punishing U.S. tariffs and promised retaliation from Europe that could send shock waves through economies around the globe.
European Commission chief Ursula von der Leyen, seated next to Trump at his golf resort on the Scottish coast, called for a rebalancing of bilateral trade worth billions of dollars between the vital partners. Speaking to reporters before their private meeting, she and Trump put the chances of reaching an agreement at 50-50 as Friday's White House deadline neared.
'This is bigger than any other deal,' Trump said. He suggested they could cut a deal in just a short time.
Story continues below advertisement
Trump called von der Leyen 'highly respected' and meeting with her at his Turnberry golf course, where he played in the morning, was an honor. 'The main sticking point,' the Republican president said, was 'fairness.'
View image in full screen
President Donald Trump meets European Commission President Ursula von der Leyen at the Trump Turnberry golf course in Turnberry, Scotland Sunday, July 27, 2025. (AP Photo/Jacquelyn Martin).
For months, Trump has threatened most of the world with large tariffs in hopes of shrinking major U.S. trade deficits with many key trading partners, including the EU.
Trump has hinted that any deal with the EU would have to 'buy down' the currently scheduled tariff rate of 30 per cent. During the remarks before the media Sunday, he pointed to a recent U.S. agreement with Japan that set tariff rates for many goods at 15 per cent and suggested the EU could agree to something similar.
Get daily National news
Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
Asked if he would be willing to accept tariff rates lower than that, Trump said 'no.'
Story continues below advertisement
Their meeting came after Trump played golfed for the second straight day at his Turnberry course on the southwest coast of Scotland, this time with a group that included sons Eric and Donald Jr. The president's five-day visit to Scotland is built around golf and promoting properties bearing his name.
View image in full screen
US President Donald Trump plays golf at his Trump Turnberry golf course in South Ayrshire, during his five-day private trip to the country. Picture date: Sunday July 27, 2025. (PA Photo: Jane Barlow/PA Wire).
A small group of demonstrators at the course waved American flags and raised a sign criticizing British Prime Minister Keir Starmer, who plans his own Turnberry meeting with Trump on Monday. Other voices could be heard cheering and chanting 'Trump! Trump!' as he played nearby.
On Tuesday, Trump will be in Aberdeen, in northeastern Scotland, where his family has another golf course and is opening a third next month. The president and his sons plan to help cut the ribbon on the new course.
Joining von der Leyen were Maros Sefcovic, the EU's chief trade negotiator; Björn Seibert, the head of von der Leyen's Cabinet; Sabine Weyand, the commission's directorate-general for trade, and Tomas Baert, head of the trade and agriculture at the EU's delegation to the U.S.
Story continues below advertisement
1:06
Trump visits Scotland to open new golf resort, sparking mixed local response
The U.S. and EU seemed close to a deal earlier this month, but Trump instead threatened the 30 per cent tariff rate. The deadline for the Trump administration to begin imposing tariffs has shifted in recent weeks but is now firm, the administration insists.
'No extensions, no more grace periods. Aug. 1, the tariffs are set, they'll go into place, Customs will start collecting the money and off we go,' U.S. Commerce Secretary Howard Lutnick told 'Fox News Sunday.' He added, however, that even after that 'people can still talk to President Trump. I mean, he's always willing to listen.'
Lutnick said the EU 'needs to make a deal and wants to make a deal and they are flying to Scotland to make a deal with President Trump. The question is do they offer President Trump a good enough deal that is worth it for him to step off of the 30 per cent tariffs that he set.'
Story continues below advertisement
View image in full screen
President Donald Trump meets European Commission President Ursula von der Leyen at the Trump Turnberry golf course in Turnberry, Scotland Sunday, July 27, 2025. (AP Photo/Jacquelyn Martin).
Without an agreement, the EU says it is prepared to retaliate with tariffs on hundreds of American products, ranging from beef and auto parts to beer and Boeing airplanes.
If Trump eventually makes good on his threat of tariffs against Europe, it could make everything from French cheese and Italian leather goods to German electronics and Spanish pharmaceuticals more expensive in the United States.
The U.S. and Britain, meanwhile, announced a trade framework in May and a larger agreement last month during the Group of Seven meeting in Canada. Trump says that deal is concluded and that he and Starmer will discuss other matters, though the White House has suggested it still needs some polishing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
23 minutes ago
- Winnipeg Free Press
The clock is ticking on tariff negotiations
Opinion It's T minus one. As in, tariffs minus one. Or Trump minus one. Or maybe even TACO minus one. Only time — precious little time — will tell. ADRIAN WYLD / THE CANADIAN PRESS FILES Prime Minister Mark Carney On Aug. 1, the Trump administration has said its self-imposed range of tariffs on myriad foreign countries — including Canada — will come into effect. (Unless it turns out to be TACO minus one — U.S. President Donald Trump has backtracked so many times on announced tariffs that he's earned the nickname 'TACO,' an acronym for 'Trump Always Chickens Out.') For Canada, that would mean a 35 per cent tariff on products not detailed in the USMCA trade deal, as well as the continuation of tariffs on aluminum, steel and automobiles, and a new copper tariff that also would come into effect on Friday. Prime Minister Mark Carney has said the negotiations between Canada and the U.S. are in an 'intense phase.' Meanwhile, the Opposition Conservatives have complained that Canada is being left behind as others reach deals with the U.S. But at least two of those deals seem to be running into confusion and contrary claims — especially because they aren't on paper yet. Trump claimed that the government of Japan bought its way into lower tariffs — going from 25 per cent to 15 per cent — by agreeing to invest US$550 billion in the U.S., an investment that Trump says would see the U.S. government get 90 per cent of the profits. Japan says it made no such offer, that if anything, the suggestions was for 'up to' US$550 billion with no set amount, and that profits from any Japanese investment would be paid on a proportional basis, based on how much each party invested. Japanese officials have also said there is no written agreement, and that there would not be one based on Trump's terms. Meanwhile, a widely heralded deal with the European Union is also hitting the shoals of Trump exaggeration: numbers on the purchase of energy by EU member states have been questioned by the EU and it now appears that all EU members will vote on a prospective deal, while Trump characterized it as a historic complete package. The EU and the U.S. also have conflicting impressions about tariffs on pharmaceuticals, tariffs on steel and aluminum, investment in U.S. companies by the EU, and purchases of U.S. weapons. For example, the U.S. version is that the EU will buy U.S. weapons, while the EU says absolutely no such commitment was made — or could be made, as military procurement is determined by individual member countries. The U.S. also claims that the EU has promised to make a range of regulatory changes to benefit U.S. exports of food and agricultural products, along with changes to financial and tax barriers on digital industries. The EU says that's a hard no — 'We're not moving on our regulations. We're not moving on our rules. We're not moving on the system that we built up over many decades that our citizens trust,' Olaf Gill, the EU Commission's spokesperson for trade said. 'That will not form part of this agreement with the U.S.' Weekday Evenings Today's must-read stories and a roundup of the day's headlines, delivered every evening. So it's all clear as mud. And what happens next for Canada? We'll find out, perhaps, on Friday. But more than anything else, move slowly and deliberately and in a calculated way, don't get rushed into a bad deal, and keep in mind that any deal is open to President Trump's penchant for exaggeration and fabrication. And for his unmatched ability to fail to live up to a signed commitment. And that's for the short term. The long term? Find new global customers. Ones that can be counted on to make an honestly negotiated deal and stick to it.
National Post
an hour ago
- National Post
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Article content OSAKA, Japan — Takeda ( TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter. The company expects these impacts to moderate in future quarters. Article content Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment to delivering sustainable value through innovation. Most notably, both Phase 3 studies of oveporexton successfully met all primary and secondary endpoints, demonstrating statistically significant improvements across doses. These results reinforce the potential of oveporexton to transform the standard of care in narcolepsy type 1. Article content In addition, Takeda received U.S. FDA approval for GAMMAGARD ® LIQUID ERC and European Commission (EC) approval for ADCETRIS ® in new indications and presented promising clinical data for rusfertide at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session. These developments underscore the strength of Takeda's late-stage pipeline and its potential to drive future growth. Article content Takeda chief financial officer, Milano Furuta, commented: Article content 'The impact of VYVANSE generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May. Article content 'Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth.' Article content Core (Non-IFRS) (Billion yen, except percentages and per share amounts) FY2025 Q1 FY2024 Q1 vs. PRIOR YEAR (Actual % change) vs. PRIOR YEAR (CER % change) Revenue 1,106.7 1,208.0 -8.4% -3.7% Operating Profit 321.8 382.3 -15.8 % -11.9% Margin 29.1% 31.6% -2.6 pp ― Net Profit 237.0 276.8 -14.4% -10.3% EPS (Yen) 151 176 -14.1% -10.0% Article content FY2025 Outlook (unchanged from May 2025) (Billion yen, except percentages and per share amounts) FY2025 FORECAST FY2025 MANAGEMENT GUIDANCE Core Change at CER (Non-IFRS) Revenue 4,530.0 — Core Revenue (Non-IFRS) 4,530.0 Broadly flat Operating Profit 475.0 — Core Operating Profit (Non-IFRS) 1,140.0 Broadly flat Net Profit 228.0 — EPS (Yen) 145 — Core EPS (Yen) (Non-IFRS) 485 Broadly flat Adjusted Free Cash Flow (Non-IFRS) 750.0-850.0 — Annual Dividend per Share (Yen) 200 — Article content Additional Information About Takeda's FY2025 Q1 Results Article content For more details about Takeda's FY2025 Q1 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda's FY2025 Q1 investor presentation (available at Article content Article content ). Article content About Takeda Article content Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Article content . Article content For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Article content The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Article content The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners. Article content Forward-Looking Statements Article content This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: Article content Article content .Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Article content Takeda's financial statements are prepared in accordance with International Financial Reporting Standards ('IFRS'). Article content This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate ('CER') change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda's management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda's non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as 'reported' measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2025 Q1 investor presentation (available at Peak Sales and PTRS Estimates Article content References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda's assessments of various possible future commercial scenarios that may or may not occur. Article content References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda's Portfolio Review Committee for use in internal planning. Article content Medical information Article content This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Article content Article content Article content Article content Contacts Article content Investor Relations Article content Article content Christopher O'Reilly Article content Article content Article content Article content Article content Media Relations Article content Article content Brendan Jennings Article content Article content Article content Article content Article content Article content Article content
Toronto Star
2 hours ago
- Toronto Star
UN investigator says US sanctions over her criticism of Israel will seriously impact her life
ROME (AP) — An independent U.N. investigator and outspoken critic of Israel's policies in Gaza says that the sanctions recently imposed on her by the Trump administration will have serious impacts on her life and work. Francesca Albanese, the U.N. special rapporteur for the West Bank and Gaza, is a member of a group of experts chosen by the 47-member U.N. Human Rights Council in Geneva. She is tasked with probing human rights abuses in the Palestinian territories and has been vocal about what she has described as the 'genocide' by Israel against Palestinians in Gaza.
